Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 25 04:00PM ET
3.50
Dollar change
-0.26
Percentage change
-6.91
%
Index- P/E- EPS (ttm)-0.25 Insider Own0.00% Shs Outstand140.27M Perf Week-17.65%
Market Cap490.95M Forward P/E- EPS next Y-0.04 Insider Trans- Shs Float140.27M Perf Month19.45%
Income-31.26M PEG- EPS next Q-0.01 Inst Own61.21% Short Float1.71% Perf Quarter17.85%
Sales8.79M P/S55.85 EPS this Y30.00% Inst Trans-6.88% Short Ratio2.24 Perf Half Y70.73%
Book/sh0.31 P/B11.46 EPS next Y-28.57% ROA-26.75% Short Interest2.40M Perf Year169.23%
Cash/sh0.35 P/C10.09 EPS next 5Y- ROE-39.59% 52W Range1.07 - 4.50 Perf YTD51.52%
Dividend Est.- P/FCF- EPS past 5Y41.78% ROI-71.76% 52W High-22.22% Beta0.89
Dividend TTM- Quick Ratio4.86 Sales past 5Y-20.00% Gross Margin63.56% 52W Low227.10% ATR (14)0.29
Dividend Ex-Date- Current Ratio4.86 EPS Y/Y TTM-21.83% Oper. Margin-469.88% RSI (14)47.72 Volatility8.52% 8.58%
Employees33 Debt/Eq0.14 Sales Y/Y TTM- Profit Margin-355.64% Recom1.20 Target Price7.20
Option/ShortYes / Yes LT Debt/Eq0.02 EPS Q/Q- Payout- Rel Volume1.57 Prev Close3.76
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsMay 15 AMC Avg Volume1.07M Price3.50
SMA20-3.83% SMA508.52% SMA20029.44% Trades Volume1,686,836 Change-6.91%
Date Action Analyst Rating Change Price Target Change
Jun-13-24Initiated Robert W. Baird Outperform $8
Oct-13-23Resumed BTIG Research Buy $4
Aug-12-22Initiated Cantor Fitzgerald Overweight $4
May-05-21Initiated BTIG Research Buy $10
Apr-05-21Initiated Needham Buy $10
Jun-15-24 11:42PM
Jun-14-24 07:50AM
Jun-12-24 07:45AM
Jun-11-24 05:47PM
May-30-24 07:30AM
04:01PM Loading…
May-15-24 04:01PM
Apr-12-24 09:35AM
Apr-03-24 07:30AM
Mar-27-24 05:27PM
04:01PM
Mar-05-24 07:30AM
Feb-16-24 03:57AM
Jan-08-24 07:00AM
Dec-19-23 11:21AM
Nov-03-23 11:43AM
04:01PM Loading…
Oct-23-23 04:01PM
Oct-14-23 04:30PM
Oct-09-23 08:00AM
Sep-21-23 07:00AM
Sep-07-23 07:30AM
Aug-10-23 11:04PM
Aug-04-23 08:12AM
Jul-07-23 07:46AM
Jul-06-23 08:00AM
May-31-23 07:00AM
May-23-23 01:43PM
May-08-23 12:46PM
May-05-23 04:06PM
Apr-21-23 12:00PM
Apr-13-23 08:00AM
04:30PM Loading…
Mar-28-23 04:30PM
Mar-21-23 06:30AM
Feb-08-23 07:00AM
Jan-10-23 05:35AM
Nov-15-22 09:35AM
Nov-08-22 07:00AM
Nov-02-22 04:01PM
Oct-28-22 07:00AM
Oct-24-22 04:30PM
Oct-21-22 07:00AM
Oct-18-22 11:58AM
07:00AM
Oct-17-22 07:00AM
Oct-03-22 05:00PM
09:00AM
Sep-28-22 09:21AM
Sep-26-22 07:00AM
Sep-14-22 09:00AM
Sep-12-22 08:00AM
Sep-09-22 08:22PM
Aug-31-22 07:00AM
Aug-22-22 04:00AM
Jul-05-22 04:01PM
Jun-21-22 08:30AM
Jun-20-22 10:36AM
Jun-17-22 05:30PM
03:53PM
10:21AM
03:44AM
Jun-02-22 08:00AM
May-26-22 05:05PM
04:30PM
May-17-22 08:00AM
May-09-22 07:45AM
07:00AM
May-06-22 05:12PM
05:12PM
Apr-22-22 09:35AM
Apr-06-22 08:00AM
Mar-31-22 04:01PM
Mar-03-22 08:30AM
Mar-01-22 08:00AM
Feb-10-22 08:00AM
Jan-12-22 01:59PM
Dec-29-21 01:19AM
Dec-22-21 07:00AM
Dec-17-21 12:38AM
Dec-15-21 09:38PM
Dec-13-21 07:00AM
Dec-10-21 09:38PM
Nov-30-21 07:00AM
Nov-09-21 08:00AM
Nov-04-21 09:00AM
Oct-31-21 10:30AM
Oct-26-21 10:26AM
08:00AM
Oct-13-21 08:00AM
Oct-01-21 04:31PM
Sep-20-21 08:00AM
Sep-09-21 08:00AM
Aug-02-21 08:00AM
Jul-19-21 07:04PM
Jun-02-21 09:45AM
08:00AM
May-27-21 08:00AM
May-04-21 08:00AM
Apr-30-21 08:00AM
Apr-08-21 08:30AM
Mar-31-21 05:02PM
Feb-25-21 11:33AM
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lewicki John A.Chief Scientific OfficerJun 21 '24Option Exercise0.0069,000073,003Jun 25 06:21 PM
Sermon CharlesGeneral CounselJun 21 '24Option Exercise0.0098,4000230,776Jun 25 06:14 PM
Scots-Knight DeniseChief Executive OfficerJun 21 '24Option Exercise0.00282,0900842,503Jun 25 06:15 PM
Hughes-Wilson AlexandraSee RemarksJun 21 '24Option Exercise0.0060,000067,650Jun 25 06:13 PM
Fox Christine AnnChief Financial OfficerJun 21 '24Option Exercise0.0090,0000100,000Jun 25 06:13 PM
Hughes-Wilson AlexandraSee RemarksMay 22 '24Option Exercise1.23168,333206,416100,983May 23 09:54 PM
Hughes-Wilson AlexandraSee RemarksMay 22 '24Sale2.97100,432297,78832,568May 23 09:54 PM